Oil-Dri Corp of America (ODC) Q2 2021 Earnings Call Transcript

Oil-Dri Corp of America (ODC 1.14%)
Q2 2021 Earnings Call
Mar 12, 2021, 11:00 a.m. ET

Contents:

• Prepared Remarks
• Questions and Answers
• Call Participants

Prepared Remarks:

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Oil-Dri Corporation of America second-quarter 2021 investor teleconference. [Operator instructions] As a reminder, today's program may be recorded. I would now like to introduce your host for today's program, Dan Jaffee, president and chief executive officer. Please go ahead, sir.

Dan Jaffee -- President and Chief Executive Officer

Thank you. And welcome, everyone, to the second quarter and six months Oil-Dri investor teleconference. We are still in a virtual environment, so our usual cast of characters will be on the call, but we're all in different places or most of us are anyway. Susan Kreh, CFO; Molly VandenHeuvel, our COO; Jessica Moskowitz, vice president and general manager of the consumer products division, Fred Kao, our VP of global sales for Amlan International; Laura Scheland, our VP and general counsel; and Leslie Garber, our manager of investor relations, are all on hand today.

And Leslie, please walk us through the safe harbor.

Leslie Garber -- Manager of Investor Relations

Thank you, Dan. Welcome, everyone. On today's call, comments may contain forward-looking statements regarding the company's performance in future periods. Actual results in those periods may materially differ.

In our press release and in our SEC filings, we highlight a number of important risk factors, trends and uncertainties that may affect our future performance. We ask that you review and consider those factors in evaluating the company's comments and in evaluating any investment in Oil-Dri stock. Thank you for joining us. Dan?

Dan Jaffee -- President and Chief Executive Officer

Yes. Thanks, Leslie. And before I turn it over to Susan for a play-by-play, I'd like to add some color to what's been going on, and we've really had a lot of positives on both sides of our major business opportunities, both the retail and the B2B. As you guys know, I took over as General Manager of Amlan International, right around November 1, and we have made some really, really good changes together.

It's been a complete team effort cross-functionally. We brought in some new players. I can distill it to people, poultry, clay and target markets. And let me start with the people.

I mean, Fred and I, Fred Kao, who's our global VP of sales, have worked really hard at building our team. Fred joining Oil-Dri was an initial badge of validation for the incredible opportunity we have because he's a 20-plus year, very successful career. He's made great contacts, and people took notice when he joined the company. And so we've been in the enviable position of being able to attract a lot of talent quickly as these people first got to know Oil-Dri through Fred, but then spend a lot of time with Molly and Hangyu and our team out at the research center, getting to get comfortable with our data that they knew had to have existed because they knew Fred was joining us for a reason.

And it's because this global vacuum that's been created by the elimination of antibiotics in the food chain, has created an incredible market opportunity for Oil-Dri. So just in this short period of time since November 1, we've been able to onboard Heath Wessels, who is covering all North America for us; Jay Hughes, who is our Americas tech service; , who's covering APAC; and then Dr. Wade Robey, who is our vice president of marketing and product development, who has had a stellar career in the animal health. We've put out news releases on this, so I encourage our investors, if you miss them, to track them down.

You can just search Amlan, and you'll find our latest news releases. But we really have created a dream team in general, but in particular, they have incredible poultry experience. So no means are we walking away from dairy or swine, but we are going to lean heavily into poultry. Poultry represents about 40% of the $3 billion global opportunity that's been created by the elimination of antibiotics in the human food chain.

And so you're talking a $1.2 billion opportunity, where from Fred to that team that I just mentioned, their -- with a quick phone call, they can get to every level at all the major decision-makers around the world, and we are getting interest like never before. So it's very, very exciting. So I mentioned people, poultry. Why didn't I mention clay? Because clay is our unique entrée into this market.

We are the only player that has quality to the source. So we have, as you well know, if you're a long time Oil-Dri investor, we have hundreds of millions of tons. We have 100 million proven, but we have to equal that amount inferred, meaning we don't even bother doing the drilling because we're not going to need it in any of our lifetimes, but mother nature put it there. So we have hundreds of millions of tons of clay to choose from, and we have specifically identified a particular reserve that has given us the highest quality and quantity of these animal health products that we're actually discovering new applications for as we speak because the more we understand our mineral, the more beneficial things we realize it's doing in the animals gut and to the animals well-being.

And so we selectively mine these. We have always a minimum of 40 years reserves in every product line. So you have no worries. As this product explodes, we have the capacity to mine and supply this industry.

You look, we may have to spend some capital along the way, but we have the reserves, and that's very exciting. So our people, our poultry and our clay. And then, finally, our target markets. We're going to fish where the fish are.

And 11 markets really are where we think we have a unique position to go after a large percentage of that $1.2 billion opportunity. My math is it's between $700 million and $800 million of that $1.2 billion, so maybe two-thirds. Don't hold me to it, but it's, obviously, large enough to dramatically change the financial landscape of Oil-Dri. And the best part is one of our most exciting markets is pristine because we have stayed away from it.

I'm not really sure why, honestly, but our prior management had decided that the South America and Asia was more important than North America. But our current team realizes we have a great right to win in America, and we are getting a lot of interest right in our backyard. It's a language I speak. It's a currency we trust.

It's contracts that are honored. And so -- and we don't have to open up new business entities to do business here. So very excited about the opportunity in the United States, and we are hitting the ground running. But as I mentioned, things financially were going to get worse before they get better.

We put on a lot of SG&A, a lot of infrastructure. And while these guys are getting a lot of interest, we are not getting a lot of orders. We've actually gotten some orders, but not enough to cover the investment we're making in people. So you're going to see our SG&A continue to trickle up in the short run, but these are all long-term investments for Oil-Dri.

None of them will impact -- it is expected, I don't think I have to qualify. Laura will definitely want me to do this, I will qualify, that it is expected that none of these will impact our ability to continue our dividend policy. These are all just using cash flow in a very wise investment pattern for the B2B side. You'll be hearing from Jessica on the retail side, and we are continuing to really gain share both with our brand and our private label lightweight.

It's very exciting. You did see in our news release that short term, we got hit with a lot of cost pressures, all at once and what she's been able to do to offset those going forward. But none of that was -- none of that pricing was able to impact the second quarter, but the cost certainly did. So that's my color.

You're going to hear get a lot of play-by-play from Susan and then, obviously, use your questions to zero in on anything that maybe we haven't clarified well enough for you. So Susan, I'd like to turn it over to you for the second quarter and six-month results.

Susan Kreh -- Chief Financial Officer

Hey. Thanks, Dan. And today, I'm going to recap the second quarter for you. So in our second quarter of fiscal 2021, Oil-Dri delivered another solid quarter of top-line growth with net sales of $74.5 million, growing 5% over net sales during the same quarter in the prior year.

Both our business-to-business products group, which grew 7%, and our retail and wholesale products group, which grew 4%, contributed to this growth, demonstrating that as Dan said, we are achieving success in two of the key areas of our strategic focus, and those are mineral-based animal feed additives and lightweight cat litter. Additionally, it was a very strong quarter within our business-to-business products group as all product lines experienced year-over-year growth in net sales. We are seeing evidence that the focus on our mineral-based strategy in animal health and nutrition products is paying off, with 20% net sales growth during the quarter over the second quarter of the prior year. Fred and his team, many of whom are new to Oil-Dri, and who Dan mentioned during his opening remarks, have done an excellent job of focusing on the strategy and are beginning to deliver on the opportunities, having just delivered on an all-time high net sales for any second quarter for Amlan International, our animal health business.

During the quarter, we saw the benefit of enhanced distribution of Varium and natural alternative to antibiotic growth promoters for poultry. We also experienced strong growth in China, Latin America and Mexico. So an all-around good story for Amlan and the investments that we're making there. Now switching to other business-to-business products.

Agricultural and horticultural products also had a strong quarter, achieving 10% growth over the same quarter in the prior year, driven primarily by increased sales with existing customers. And in our fluids purification products, the decrease in sales of our jet fuel purification products that have been adversely impacted by the reductions in air travel due to the global pandemic were more than offset by the growth of our other products as our overall fluids purification products grew 3% in the quarter over the prior year. This growth was favorably impacted by increased sales to our foreign customers during the quarter. And finally, our co-packaged cat litter product, which sits within our business-to-business products portfolio, grew 5% during the second quarter of fiscal 2021.

Now similarly, within our consumer products group, cat litter sales grew 6% over the prior year. We believe that our continued strategic focus on growing our lightweight litter products contributed to this growth in both the U.S. and Canada. We also experienced increases in private label and branded scoopable litter sales, as well as growth through e-commerce sales.

Switching gears. Our second-quarter gross profit of $18.2 million was down $800,000 from the same quarter in the prior year, representing a 4% year-over-year decrease. During the quarter, we experienced some significant cost challenges, which Dan alluded to in his opening remarks. Despite the favorable growth in net sales, the quarter was unfavorably impacted by cost increases particularly in the categories of freight, which was up 13% per manufactured ton over the same quarter in the prior year due to domestic trucking supply constraints that resulted in significant increases in transportation costs.

Our packaging costs were also up 13% per manufacturing ton as increased resin pricing resulted in increased costs, particularly in our jugs and pales, and natural gas costs were up 8% per manufactured tons, which we used to operate kilns to dry our clay. Overall, our cost of goods sold per manufactured ton was up 8% over the same quarter in the prior year, driven, in large part, by these market-based factors that were partially offset by operating cost reductions and efficiencies during the quarter. We responded to the significant cost challenges posed by these economic headwinds through implementing mid-fiscal-year price increases. So all of our products are impacted to various extents.

consumer cat litters particularly impacted due to the amount of freight and resin-based packaging costs that are included in those products. Switching to our total selling, general and administrative expenses for the second quarter of $13.9 million, they were $843,000 higher than the prior year, representing a 6% increase. However, the second quarter of the prior fiscal year included a onetime curtailment gain of $1.3 million related to the freeze of the company's supplemental executive retirement plan, which has since been terminated. Excluding that $1.3 million onetime gain in the prior year, SG&A was down 3% during the quarter.

However, there was also an underlying shift in costs as corporate expenses, including the impact of the fiscal 2020 onetime gain or excluding the impact of the onetime gain of $1.3 million, decreased from the prior year and SG&A costs to support our business-to-business products, particularly the investments that we're talking about in our animal health and nutrition products, grew 26% or approximately $600,000 over the same quarter of the prior year. This incremental expense is consistent with our commitment to invest in this high value-add product line to drive growth for our future, and Dan did share some of those highlights at the beginning of the call. Our second-quarter other income of $1.1 million included an $800,000 gain upon the annual actuarial valuation of our pension plan. So as a reminder, during the fourth quarter of fiscal 2020, the company executed a lump sum buyout for the terminated vested participants in our defined benefit pension plan who had elected to take this buyout payment option.

A majority of the participants that were eligible for this lump sum buyout opted to take it, which contributed to the favorable annual actuarial valuation of this obligation. And finally, net income attributed to Oil-Dri for the second quarter of fiscal 2021 was $4.3 million, which represents an 11% decrease from the prior year for the cost and investment reasons we just reviewed. Our financial position remains strong, as is reflected in our balance sheet. We ended the quarter with cash and cash equivalents of $31 million and have very little debt, equating to a debt to total capital ratio of only 6%.

The one of the primary uses of our cash flow is to fund our trade working capital. During the first six months of fiscal 2021, our accounts receivable increased $3.8 million, reflecting our sales growth and a shift in our customer mix, including an increase of sales to foreign customers who tend to have longer payment terms. We also use our cash to fund capital investments in our business, including those required for growth and those required to drive cost reductions, in addition to normal repair and replacement capital. Because of our strong position during the quarter, we also repurchased 33,594 shares of Oil-Dri common stock for $1.2 million at an average price of $36.09 per share.

So based on our strong financial position, we often get asked if we are interested in pursuing acquisitions. And the answer is, yes, for the right opportunity. Because of our low leverage, we are well-positioned to capitalize on strategic investment opportunities that may become available. So that's my summary for the second quarter.

And with that, Dan, I'm going to turn it back over to you so people can ask questions.

Dan Jaffee -- President and Chief Executive Officer

Perfect. Thank you very much. Great summary. So yes, at this time, I'd like to open up to Q&A.

[Operator instructions]

Questions & Answers:

Operator

Thank you. [Operator instructions] Our first question comes from the line of Ethan Star, a private investor. Your question, please.

Unknown speaker

Yeah, hi, good morning. I know you're in trials with some of the top poultry integrators in America. And I'm wondering how are those trials going? And how long might it take to convert those trials into sales?

Dan Jaffee -- President and Chief Executive Officer

Sure. Well, if you know that, then you know more than I do. So we have not disclosed, nor am I gonna to confirm nor deny we are in any trials with large poultry integrators in America. And even if we were, I wouldn't tell you because honestly, until -- as you know me well enough, until we're in the end zone, we don't celebrate.

So we have nothing material to report at this time on that front. But I'll let you ask another question because I didn't really answer your question.

Operator

Thank you. [Operator instructions] Hi, Ethan, your line is open again.

Unknown speaker

Do you see the sales cycle decreasing in terms of length of time to sales?

Dan Jaffee -- President and Chief Executive Officer

I will let Fred talk about the sales cycle, Fred?

Fred Kao -- Vice President of Global Sales, Amlan International

Can you repeat that sales cycle decrease? I didn't understand that.

Dan Jaffee -- President and Chief Executive Officer

Yeah. I mean, I don't think it's really gonna decrease, so I'll lead you in the right direction. Just generally talk about the sales cycle. I mean, what do you think it takes to go from the first time we contact an account to potentially getting a real order, not a trial, but a real order.

Fred Kao -- Vice President of Global Sales, Amlan International

OK, understood, and a good question. So it really depends on the species, right? If we have a chicken poultry company that contact with us, the sales cycle will likely be anywhere between three to six months because usually for the customers to be convinced, they would like to have a couple of trials in place. So that's the normal time. If the -- for swine market, this is gonna be much longer, depending on the usage, if they're using on a breeding side of the sales, then that cycle is gonna be dragging out for more than a year and a half, right? But if they're using on the piglets, so it is shorter, but we are still looking at a year cycle, a year and a half cycle timing.

Dan Jaffee -- President and Chief Executive Officer

So it's clearly a lengthy cycle. But then on the flip, if and when they adopt, they're very slow to change. So then you're in there for a while and hopefully forever, obviously, the goal. But they don't make quick decisions.

There's too much at stake, and they're going to be very methodical in their decision-making process. But great question. Next?

Operator

Our next question comes from the line of Robert Smith from the Center for Performance. Your question, please.

Robert Smith -- Center for Performance -- President and Chief Investment Officer

Yes, good morning. Thanks for taking my question.

Dan Jaffee -- President and Chief Executive Officer

Hi, Rob.

Robert Smith -- Center for Performance -- President and Chief Investment Officer

Hi. So congratulations on -- I have, for a long time, felt that Amlan was gonna be the tailed that wagged the cat, so to speak. And I'm glad to see the initiatives that are being taken. My first question would revolve around, you mentioned 11 markets.

Can you name the markets for me?

Dan Jaffee -- President and Chief Executive Officer

I mean, we could, but again, it would only hurt your investment. So no. Other than America, we're not gonna name exactly which markets we're going to. That just tips off the competition too well.

Robert Smith -- Center for Performance -- President and Chief Investment Officer

Well, I assume there's a larger countries and the countries that have been named in the past, I mean.

Dan Jaffee -- President and Chief Executive Officer

Well, I mean, I just wouldn't make any assumptions other than the opportunity is -- what you need to focus on is that it's two-thirds of the $1.2 billion opportunity. So it's large. It's not like it's 11 countries that together only are buying $50 million worth of antibiotic. So it's a great opportunity.

Robert Smith -- Center for Performance -- President and Chief Investment Officer

So you mentioned in the prepared remarks that China had this big increase. I assume it's off a very, very low number, so to speak. Is that --

Dan Jaffee -- President and Chief Executive Officer

I'll let Fred talk about China.

Fred Kao -- Vice President of Global Sales, Amlan International

Bob, not really, I won't say it's based on very low number, right? So as Dan and Susan mentioned earlier, we were able to close on the existing customers, one of the biggest company in China. And based on that, it was giving us a huge boost on our existing business. And on top of that, we're able to bring back some of the old distributors that we have relationship with, where we kind of lost connection because of the previous team, right? And we are able to gain on that. And so that 100 products, 40% growth that we're seeing Quarter 2 is really has a lot to do with not because of the small numbers we had before, really because of the potential we're building on, right? So you'll be able to see that in upcoming quarters.

So I guess, that's probably the best way to explain that.

Operator

Thank you. Our next question comes from the line of John Bair from Ascend Wealth Advisors. Your questions, please.

John Bair -- Ascend Welth Advisors -- Analyst

Good morning. First off, I wonder what -- Dan what brand coffee you're drinking? I don't think I've ever heard you quite as animated in your opening comments as you were. So with that aside, you can get back to me on that. So it sounds like there's a shift -- your emphasis is shifting from -- maybe from the international, let's say, from your focus on China, previously, and now more of a focus domestically.

And also, I guess, that would mean going from focusing on the swine market versus the poultry. But I've read a lot about how the swine market is trying to be rebuilt in China and so forth. So I'm just wondering how that aspect of Amlan's business is proceeding.

Dan Jaffee -- President and Chief Executive Officer

All right. Well, I'm gonna let Fred answer the question about China. I'll answer the question about my coffee. It's Peppermint Bark, ice coffee.

And yes, I am -- but I'm really excited about the opportunity. I drink that every morning. So what you're saying to me, is I'm excited. But Fred, talk about China and what species we're seeing business from? And where we see maybe the future?

Fred Kao -- Vice President of Global Sales, Amlan International

Yeah, thank you. So for China, right, the species, actually we're working on multiple, right? So right now, the biggest opportunity like you mentioned earlier is swine because I think that's where -- would African swine fever and people on companies are coming out of Africa and swine fever. They're focused on making sure that the population of the pigs are actually healthy. So we're seeing a huge boost in that field.

At the same time, we are seeing a really nice increase in the remnant market as well, right? So I think it's not just on the swine market, but both. But just to add a little bit on the swine market. Also with African swine fever, that's the increased risk of the vulnerability of that market, right, because we don't really have a way of making sure that pigs are staying healthy, not harmful way from the virus. So that's a challenge we are faced with.

But at the same time, we actually give us opportunity because people are willing to invest more on making sure the healthy flock is maintained, right? So that gives us a different opportunity to get into the market as well.

John Bair -- Ascend Welth Advisors -- Analyst

Great. Thank you.

Operator

Thank you. Our next question is a follow-up from Ethan Star. Your question, please.

Unknown speaker

Yeah, I'm just wondering, so what kind of top feedback do you get from your existing customers for Amlan? The NeoPrime and Varium. What feedback do you get in the results and their return on investment, that kind of thing? And what -- does that help you get additional customers?

Dan Jaffee -- President and Chief Executive Officer

Fred?

Fred Kao -- Vice President of Global Sales, Amlan International

Yeah, I can take that, right, Dan? Or --

Dan Jaffee -- President and Chief Executive Officer

Yeah.

Fred Kao -- Vice President of Global Sales, Amlan International

OK. Well, very, very positive, Ethan. So what we're seeing right is, the customers -- you asking about a turnaround kind of circle, right, if we have customers using Varium, the only thing we've seen that increasing the number of tonnage they're ordering, we have not seen a customer that started using Varium and started reducing the tonnage of orders since I've joined the company. So it's a very, very nice and positive trend.

For NeoPrime, it's the same, we're seeing the same trend as it takes time to convince customers actually to use our product. But once they start using it and seeing that the effect that has on as -- and a wise alternative, we're only seeing the trend going up. And that's really encouraging, and that's the key message that I think I can give you here.

Dan Jaffee -- President and Chief Executive Officer

And I'm gonna add on to this just anecdotally or generally. Because Fred and Jay and Heath and Wade really and Herald are really able to understand the data in the test and turn it because they've got so much experience in this industry, put it in terms that the decision-makers are motivated to keep moving forward. So for instance, we've been myopically focusing historically on feed conversion ratio, which is what's the cause of the input? And what do you get out of it in terms of weight gain or whatever it is you're trying to get out of the reason why you're raising the animal? So let's just call it in poultry, weight gain. Well, we recently did a study, a test with a big player in a big country, and I'm not going to get into the details, but we need to get into is why is Dan so excited.

It's twofold. I've always believed in our products. I've always believed in it, but we had a test with them where the feed conversion ratio of us against the control was about identical. So there were members of our team that we're perceiving this as a failed trial because why would you buy our product if you're not going to increase the feed conversion ratio.

Fortunately, Fred was on the call. It was 11:00 at night, his time. He works 24 hours a day. And he's like -- but look at the mortality rate, meaning so our mortality rate was so much lower with our product that we could have actually had a lower feed conversion ratio and still had it been a positive spend for the customer.

But to be able to achieve an equal FCR and decrease your mortality rate. For example, let's say you put 1,000 birds in, and I'm just making up numbers, we decreased the mortality rate by 10%. So we get out 1,000 birds, but the control only get out 900 birds. Yes, the FCRs are the same, but by using our product, they have 100 more birds to sell, which is an 11% increase over the 900.

So it's an unbelievable economic windfall. And once the customer looked at the data in that way, they were very excited. So it went from where we were thinking we had failed the test because we didn't really understand how to look at the data, to someone with Fred's experience being able to say not only is this not a bad test, these are the best results pretty much he's ever seen. I'll let him speak for himself.

And it was a glowing success. So yes, I'm very excited about this opportunity. Fred, did I recap that pretty well?

Fred Kao -- Vice President of Global Sales, Amlan International

Yeah. And I just want to add. Thanks, Dan. That's really -- the thing we're talking about is the total number of output, right? So if we're able to have more birds in the chicken houses of using our product, the output, I mean, right, and the mix that you don't really see it in terms of -- on a statistical sheet.

But if you do a calculation based on dollar amount, that's a huge advantage on our product. And that's what Dan says, interpretation of the data, right, needs to be done properly, and we need to educate the customers and understand best where we come in. We may not win on one thing, but at the bottom line, that's the most important number, right, if we won a dollar amount then we're actually a big winner.

Dan Jaffee -- President and Chief Executive Officer

Excellent. And we're out of time, but it's fine. We've covered honestly, as an investor, and I'm the biggest investor here, we've covered what you need to know to be hopefully, as enthusiastic about the long-term prospects. It's gonna take time, but the ship is starting to turn, and it starts with the people and the strategy, and then we've got the support team.

By the way, thank God, we invested in the ERP system a few years ago. Thank God, we dramatically improved the talent level of the company, from Susan to Molly to Laura to Jessica to Fred, and I can go on and on and on. I hate to eliminate anybody. But the fact of the matter is Oil-Dri is well-positioned and well-poised at this point in time to take advantage of this opportunity.

Had this opportunity hit three years ago, it would have killed us. And now we are ready for it. I'm not telling you we're not going to have problems, and that we won't feel some stress fractures. Those will be nice problems to have because it will mean the business is booming.

But we are in great shape to take advantage of this. And so thank you for your interest. We'll be back at you again after the third quarter and nine months. And I'll stay on my coffee because it's working.

Take care.

Operator

[Operator signoff]

Duration: 32 minutes

Call participants:

Dan Jaffee -- President and Chief Executive Officer

Leslie Garber -- Manager of Investor Relations

Susan Kreh -- Chief Financial Officer

Unknown speaker

Fred Kao -- Vice President of Global Sales, Amlan International

Robert Smith -- Center for Performance -- President and Chief Investment Officer

John Bair -- Ascend Welth Advisors -- Analyst

More ODC analysis

All earnings call transcripts